Reliance Life receives FDA warning

The U.S. Food and Drug Administration issued a warning letter on August 18 to Reliance Life Sciences Private Limited after a February inspection of the company’s Navi Mumbai drug manufacturing site found significant current good manufacturing practice violations. The letter was addressed to Santhosh Mathai, business head-pharmaceuticals, and covers the plant at the Dhirubhai Ambani Life Sciences Centre in Rabale, Navi Mumbai. FDA said the inspection ran from February 19 to February 27, 2026, and that the site’s methods, facilities or controls did not conform to CGMP requirements for finished pharmaceuticals. The FDA letter says the deficiencies were serious enough that the company’s drug products are considered adulterated under section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act. The agency said it had reviewed Reliance’s March 20, 2026 response to a Form 483 and subsequent correspondence before issuing the warning. (fda.gov) ### Which facility did the FDA cite, and who received the letter? Reliance Life Sciences Private Limited was identified in the warning letter by FDA Establishment Identifier 3009510975. The cited address was Dhirubhai Ambani Life Sciences Centre, R-282 TTC Area of MIDC, Thane Belapur Road, Rabale, Navi Mumbai, Maharashtra 400701, India. The letter was sent to Santhosh Mathai in his role as business head-pharmaceuticals. (fda.gov) ### What did FDA say inspectors found inside the plant? The FDA said Reliance failed to ensure laboratory records included complete data from tests needed to show products met specifications and standards. The agency’s public letter summary also points to breakdowns in storage, status control and batch traceability as core deficiencies tied to material and record control. (fda.gov) The warning letter states that the violations described are not an all-inclusive list. FDA told the company to address the cited failures promptly, allocate appropriate resources and prevent recurrence. ### Why does a warning letter matter for exports to the United States? (fda.gov) The FDA told Reliance that failure to adequately address the violations may result in regulatory action without further notice. The agency said that could include continuing to refuse admission of articles manufactured at the Navi Mumbai site into the United States. (fda.gov) FDA’s warning-letter page says matters described in warning letters may later be affected by subsequent interaction between the agency and the recipient, and that updated status information may require direct contact with FDA. ### What does the agency want Reliance to do now? (fda.gov) The August 18 letter tells Reliance to identify root causes and implement corrective and preventive actions. FDA said the company should fully address the violations without delay and ensure resources are in place to stop them from recurring. (fda.gov) The agency said it had already reviewed Reliance’s initial response to the inspection observations, which means the next step is documented remediation that satisfies FDA. The warning letter remains publicly posted on the FDA website under the company’s name and reference number 320-26-117. (fda.gov) ### Where can readers track the next step? The FDA posted the Reliance Life Sciences warning letter in its warning-letters database, where any later response or closeout would typically appear if published. The current posting identifies the company, the August 18, 2026 issue date and the CDER office that issued it. (fda.gov)